Kornimate/medical-research-clean huggingface dataset:
satisfaction of patients with trans-arterial radial access: quality of life in uterine fibroid embolization trial

Conditions: Uterine Fibroid

Summary: randomized trial comparing uterine fibroid embolization patient satisfaction and quality of life with femoral versus radial arterial access

1:1 randomized trial comparing patient satisfaction and quality of life with femoral versus radial arterial access for uterine fibroid embolization

Eligibility criteria:
inclusion criteria: * meeting standard eligibility criteria for uterine fibroid embolization * satisfactory ulnopalmar arch patency exclusion criteria: * unable to provide informed consent * unable or unwilling to complete the study questionnaires * failed barbeau test

Keywords: uterine fibroid embolization uterine artery embolization arterial access radial access interventional radiology quality of life patient satisfaction patient centered care uterine fibroid
cortical function changes during swallowing in patients with dysphagia in lateral medullary syndrome

Conditions: Deglutition Disorders; Lateral Medullary Syndrome

Summary: the goal of this observational study is to detect the alteration of cortical activation and functional connectivity during swallowing in patients with lateral medullary syndrome (lms) dysphagia by functional near infrared spectroscopy (fnirs). the main questions it aims to answer are: * the alteration of cortical activation during swallowing in patients with lms compared with healthy subjects. * the alteration of cortical functional connectivity during swallowing in patients with lms compared with healthy subjects. fnirs will be used to detect cortical activation and functional connectivity during swallowing tasks in lms patients and healthy subjects, and to compare the differences between patients and healthy subjects.


Eligibility criteria:
inclusion criteria: * the first ischemic stroke was confirmed by head mri as lms; * 18-80 years old, right-handed; * dysphagia was confirmed by video fluoroscopic swallow study(vfss); * conscious enough to cooperate with fnirs testing; * no previous neurological or mental illness. exclusion criteria: * other central nervous system diseases (parkinson's disease, alzheimer's disease, intracranial tumors, etc.); * other diseases causing dysphagia (tumors of the esophagus, larynx, nasopharynx, etc.); * serious physical diseases (cancer, fracture, etc.); * other mental disorders (mania, schizophrenia, etc.); * unconscious, unable to cooperate with the examination
problem solving training and low vision rehabilitation

Conditions: Low Vision

Summary: vision loss can result in feelings of frustration, helplessness, anxiety, depression, and anger, which compromise a person's activities of everyday living. while emotional distress may resolve in some persons without intervention, unmanaged and persistent distress places the person at risk for continued decrements in health status and the potential development of more severe conditions (i.e., depression, poor health outcomes). persons with low vision will be recruited and randomly assigned to either an innovative, problem-solving training (pst) intervention group designed specifically for persons with low vision or a sham intervention/control group. primary and secondary outcomes will be assessed at baseline prior to intervention and at 3 month follow-up, 7 month follow-up, 12 month follow-up, and 24 month follow-up by a research interviewer masked to participants' randomization. this project will: (1) demonstrate how specified physical and emotional outcomes of persons with low vision change across time, (2) evaluate the effectiveness of a pst intervention that will be delivered to persons with low vision; and (3) identify persons with low vision who are at risk for adverse emotional and health outcomes.


Eligibility criteria:
inclusion criteria: * +19 yrs of age * underwent a low vision rehabilitation initial eye exam * no more than 2 errors on cognitive on cognitive screening measure (spbs) * must have access to telephone * no significant hearing problems * no significant communication problems * speaks fluent english
uromune in treating recurrent urinary tract infections in women

Conditions: Recurrent Uti

Summary: to determine the effectiveness and safety of the vaccine uromune in canadian women with recurrent urinary tract infection.

the proposal is for a real life clinical practice study in which female participants with a predefined history of recurrent utis in the previous year will be treated with 3 months of oral vaccine with a further 9 months of follow-up. the primary outcome will be no uti in the 9 month efficacy period following completion of the vaccine (definition of a responder). a clinically significant and important outcome will be defined as a responder rate of 50% (50% of participants who had at least 3 utis in the previous year reporting no utis after therapy initiated.

Eligibility criteria:
inclusion criteria: * can provide written consent and willingness to comply with all aspects of study treatment and study requirements. * individuals who have had at least 3 episodes of a uti in the past 12 months or 2 uti episodes in the past 6 months. at least one of the uti episodes must be associated with a positive urine culture with a traditional uropathogen including escherichia coli, proteus spp. staphyloccous sp. enterococcus sp. klebsiella sp. or pseudomonas aeruginosa. * post-menopausal for a minimum of 1 year or negative pregnancy test if participant is of child bearing potential and agreement to acceptable contraceptive use from screening visit 1 to final follow up visit if participant is sexually active. medically acceptable methods of contraception include hormonal contraception (i.e. estrogen, and/or progesterone or preparations that contain a combination of these hormones), non-hormonal intrauterine device or double barrier method (i.e. condom with foam or vaginal spermicidal suppository, or diaphragm with spermicide) or vasectomy of sole sexual partner. complete abstinence alone can be used as a method of contraception. * free of a urinary tract infection at the time of trial inclusion. exclusion criteria: * history of bladder tumours including uterine, cervical, vaginal or urethral cancer. * worrisome post-voiding residual (investigator's discretion). * infection related to urinary lithiasis. * any immunological disease requiring active therapy. * currently receiving immunotherapy. * taking any prophylactic antibiotics at screening. any prophylactic antibiotics must be stopped the day of the screening visit. * any known intolerance to the ingredients of the uromune® immunotherapy. * have any other condition or disease which, in the opinion of the investigator, could compromise participant safety or interfere with the participant's participation in the study or in the evaluation of the study results.
gtscope - to evaluate the natural progression of dry age-related macular degeneration (amd)

Conditions: Dry Age-related Macular Degeneration; Macular Degeneration; Retinal Disease; Retinal Degeneration; Geographic Atrophy; Macular Atrophy

Summary: an observational study to evaluate the natural progression of dry amd in genetically defined subjects

prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with ga due to amd.

Eligibility criteria:
inclusion criteria: 1. adults with unilateral or bilateral geographic atrophy (ga) due to age-related macular degeneration (amd) 2. bcva of 40 letters or better using etdrs charts exclusion criteria: 1. evidence or history of neovascular age-related macular degeneration (amd) or diabetic retinopathy 2. significant ocular or non-ocular disease that would impact the subject's ability to participate in the study 3. participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline or received a gene/cell therapy at any time previously
clinical research of robo1 specific car-nk cells on patients with solid tumors

Conditions: Solid Tumor

Summary: immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. we have developed anti-robo1 car-nk cells that can target tumor cells highly expressing robo1. the purpose of this study is to evaluate the safety and effectiveness of cell therapy using robo1 car-nk cells to treat solid tumors.


Eligibility criteria:
inclusion criteria: 1. age 18 \~ 75 years old, male or female 2. life expectancy ≥ 6 months 3. ecog score: 0 - 3 4. robo1 expression in malignancy tissues detected by immuno-histochemistry (ihc) 5. advanced solid tumor was diagnosed by pathological or clinical physicians 6. laboratory examination: white blood cell ≥ 3 x 10\*9/l, blood platelet count ≥ 60 x 10\*/l, hemoglobin ≥ 85g/l; lymphocyte count ≥ 15%, total bilirubin ≤ 100 mol/l; alt and ast less than five times of the normal level; serum creatinine less than 1.5 times of the normal level 7. signed informed consent 8. women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cell transfusion exclusion criteria: 1. expected overall survival \< 6 months 2. patients with uncontrolled hypertension, unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> class ii, nyha), or myocardial infarction within 6 months 3. abnormal lung function: fev (forced expiratory volume) \< 30% prediction, dlco (diffusing capacity of the lung for carbon monoxide) \< 30% prediction, blood oxygen saturation \< 90% 4. other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc. 5. unable or unwilling to provide informed consent, or fail to comply with the test requirements
topical betaxolol for the prevention of retinopathy of prematurity

Conditions: Development of Side Effects From Betaxolol

Summary: we hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

the drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when rop is most likely to arise.

Eligibility criteria:
inclusion criteria: * \<1251 grms birth weight exclusion criteria: * ocular defect

Keywords: betaxolol/ retinopathy of prematurity
enhanced recovery after surgery (eras) in coronary artery bypass graft / off pump coronary artery bypass (cabg/opcab)

Conditions: Coronary Artery Disease; Coronary Stenosis

Summary: it has been assumed that some elements of the eras protocol may contribute to the reduction of complications and improve the satisfaction of patients undergoing coronary artery bypass surgery. elements of the eras strategy will be tested in this study. the elements that prove to be feasible and have a positive effect on the treatment process will be introduced into everyday clinical practice. in the next stage of the research, we are planning to investigate whether the introduction of the eras strategy has had a long-term positive effect on the quality of life after treatment (a survey 1 month and 6 months after leaving the hospital).

evaluation of the impact of implemented elements of the eras strategy on the results of surgical treatment of coronary artery disease in the aspect of: * preoperative preparation (comprehensive information, premedication, hydration), * haemodynamic stability (discontinuation of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers immediately before surgery), optimal pre- and intraoperative fluid therapy, * occurrence of respiratory complications (assessment of the duration of mechanical ventilation and passive oxygen therapy), * demand for painkillers in the postoperative period, after introducing the preemptive strategy, * incidence of postoperative delirium, * time to recovery of the normal bowel function (nausea, vomiting), * possibility of early mobilisation on the first day after surgery, * patient's satisfaction with treatment assessed on the basis of a survey carried out on the day before leaving the hospital.

Eligibility criteria:
inclusion criteria: * cabg/opcab (coronary artery bypass surgery/off pump coronary bypass surgery). * left ventricular ejection fraction above 35% (ef ≥ 35%). * the operation was performed in a planned mode. exclusion criteria: * haematological diseases and the associated increased risk of bleeding in the early postoperative period. patients taking anticoagulants until the day of surgery with the exception of aspirin. * neurological disorders, stroke with persistent symptoms, dementia. * chronic lung disease with hypoxia and the need for regular medication. * inability to move independently, disability preventing efficient rehabilitation, prolonged use of painkillers. * emergency surgery, reoperation. * return to the operating room regardless of the reason (resternotomy). * perioperative infarction with circulatory destabilization.

Keywords: coronary artery bypass surgery/grafting, eras
prosthetic performance enhancement trial

Conditions: Amputation; Lower Limb Amputation Below Knee (Injury); Lower Limb Amputation Above Knee (Injury); Lower Limb Amputation at Ankle (Injury); Lower Limb Amputation Knee; Lower Limb Amputation at Hip (Injury)

Summary: the purpose of this research is to determine the feasibility of an uneven terrain walking program for lower limb prosthesis users. the training is designed to induce step-to-step variability during walking within a safe environment, with the aim of improving walking skill and confidence.

despite advances in the technology for artificial limbs (prostheses), falling and the fear of falling continue to be barriers to mobility for many lower limb prosthesis users after their initial rehabilitation. the loss of ability and confidence in pursuing everyday tasks negatively impacts quality of life, and ongoing physical and mental health. this study will test and improve a rehabilitation training intervention involving walking on uneven ground to improve walking skill and confidence in lower limb prosthesis users. lower limb prosthesis users will be recruited. participants will be allocated randomly to receive either intervention a: training on a flat surface, or intervention b: training on an uneven surface. depending on their ability and confidence, participants will complete the walking practice either on a treadmill or on a mat with an identical surface pattern. the walking practice will take place three times per week for four weeks. as each participant improves their ability, training tasks will be made more difficult by limiting handrail use, by increasing walking speed, and, for intervention b, also by making the walking surface more uneven. the objectives of this pilot study are to evaluate adherence and refine the training protocols in preparation for a definitive trial that will inform rehabilitation practices.

Eligibility criteria:
inclusion criteria: * lower limb amputation at ankle (symes) level and above * age 18+ years * fitted with a walking prosthesis and use it regularly for home and/or community ambulation * good socket fit, assessed by a score of 8-10 on the socket fit comfort scale * able to walk for three minutes at a time with or without an assistive device exclusion criteria: * leg/foot ulcer or other conditions that cause pain during weight-bearing * poor skin integrity that could cause tissue breakdown by walking * cardiovascular, respiratory or other critical health conditions that preclude moderate physical activity * unilateral or bilateral upper limb absence or loss at the wrist and above that precludes use of handrails bilaterally, or would require asymmetrical adaptation to body posture for use. * pregnancy
evaluating residual congestion at discharge in acute heart failure patients

Conditions: Acute Heart Failure (AHF); Congestive Heart Failure(CHF)

Summary: treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. nevertheless, current evidence shows that decongestion is often not achieved and that residual congestion at discharge is strongly associated with poor outcomes. while this association has been demonstrated, previous studies have primarily focused on single parameters of congestion (physical examination, biomarkers, or imaging features). the aim of our study is to assess residual congestion at discharge using a multiparametric approach and to compare the prognostic value of each evaluation strategy. additionally, our analysis will be supported by artificial intelligence to develop a multiparametric prognostic algorithm that can provide an improved predictive model compared to standard statistical approaches.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * patients hospitalized for new onset heart failure or worsening heart failure defined by: 1. symptoms classified as new york heart association class iii or iv. 2. clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on x-rays or lung ultrasound, pitting edema, and jugular venous distension). 3. elevated nt-probnp levels within the first 24 hours of admission (cutoff values: 450 ng/l for patients \ 900 ng/l for patients aged 50-75 years; \>1800 ng/l for patients \>75 years). * ability to provide informed consent. exclusion criteria: * known diagnosis of septicemia. * glomerular filtration rate \< 15 ml/min. * life expectancy \< 6 months. * active myocarditis. * heart transplant recipients. * patients with ventricular assist devices. * congenital heart diseases. * moderate-to-severe liver disease (child-pugh b-c). * patients that will not be followed up by the heart failure unit.

Keywords: acute heart failure residual congestion multiparametric assessment risk stratification
diabetter together for young adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: diabetter together is a strengths-based peer support intervention delivered to young adults (age 17-25) by trained peer mentors (age 20-35) during the transition between pediatric and adult diabetes care. the aims of this proposed randomized controlled trial are to evaluate the impact of the intervention on glycemic control (primary), time to first adult care visit, adherence, and psychosocial outcomes (secondary) in young adults with t1d after 12 months.

diabetter together is a strengths based peer support intervention delivered to young adults (age 17-25) by trained peer mentors (age 20-35) during the transition between pediatric and adult diabetes care. the study aims to optimize transition in t1d by leveraging and building on young adults' diabetes strengths, self-management skills, and social supports. this intervention will maximize protective processes that can facilitate optimal transition by training peer mentors (experienced young adults with t1d who have successfully established care in an adult setting) to provide relevant information about successful transition, teach strengths-based skills for managing transition-related challenges, share personal transition-related experiences, encourage young adults to access their social support network, and serve as a positive role model. delivery of these strengths-based intervention components through a peer mentor has potential to reduce isolation, increase access to relevant information, and facilitate engagement with self-management and t1d care. this intervention is a complement to existing systems of care for young adults with t1d for 12 months as they leave the pediatric setting.

Eligibility criteria:
young adult inclusion/exclusion criteria inclusion criteria: * has a diagnosis of type 1 diabetes of at least 1 year * currently receiving care at a texas children's hospital diabetes care center location * is between the ages of 17-25 years at enrollment * exhibits fluency in reading/speaking english * their endocrine provider confirmed plans to transfer to adult provider in the next 6 months exclusion criteria: * serious medical, cognitive, or mental health comorbidity that would preclude ability to provide informed consent or participate in data collection or intervention peer mentor inclusion/exclusion criteria inclusion criteria: * was diagnosed with type 1 diabetes before age 18 * has a diagnosis of type 1 diabetes of at least 1 years * is between the ages of 20-35 at enrollment * has been previously treated in pediatric care and is currently treated in adult care * demonstrated interest and ability to effectively deliver the peer intervention \& * exhibits fluency in reading/speaking english exclusion criteria: * serious medical, cognitive, or mental health comorbidity that would preclude ability to fulfill role or complete questionnaires.

Keywords: peer support adherence young adult quality of life transition resilience strengths-based sleep covid-19 experiences
study of vn-0200 in japanese healthy adults and elderly subjects

Conditions: Respiratory Syncytial Virus Infections

Summary: this study will assess the safety, tolerability, and immunogenicity of vn-0200 after intramuscular injections in japanese healthy adults and elderly subjects.


Eligibility criteria:
inclusion criteria: * japanese * healthy adults aged ≥20 and ≤50 years (step 1) or healthy elderly aged ≥65 and ≤80 years (at the time of informed consent) * body mass index (bmi) is ≥18.0 and \<30.0 kg/m\^2 (at screening) exclusion criteria: * participants with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination * having alcohol or drug dependence, etc.

Keywords: respiratory syncytial virus infections vn0200